8-K: EyePoint Initiates Phase 3 for DURAVYU in DME

EyePoint Pharmaceuticals announces the initiation of its pivotal Phase 3 program for DURAVYU in diabetic macular edema, supported by new multi-mechanism of action data.

Summary

• EyePoint Pharmaceuticals initiated its pivotal Phase 3 program for DURAVYU (vorolanib intravitreal insert) for the treatment of diabetic macular edema (DME).
• First patient dosing in the Phase 3 DME trials (COMO and CAPRI) is anticipated in the first quarter of 2026.
• New preclinical data demonstrates that vorolanib, the active drug in DURAVYU, inhibits both VEGF-mediated vascular permeability and IL-6 mediated inflammation, positioning it as a potential multi-mechanism of action (MOA) treatment.
• The Phase 3 DME program consists of two identical non-inferiority trials, each enrolling approximately 240 patients, who will be randomly assigned to either a DURAVYU 2.7mg arm or an on-label 2mg aflibercept control arm.
• The primary endpoint for the DME trials is the change from baseline in best corrected visual acuity (BCVA) to weeks 52 and 56, blended, compared to on-label 2mg aflibercept.
• Estimated cash and investments on hand as of September 30, 2025, are over $200 million, providing a cash runway into 2027, beyond Phase 3 wet AMD data.
• DURAVYU is also currently being evaluated in two Phase 3 pivotal trials for wet age-related macular degeneration (wet AMD), with data anticipated in mid-2026.

Sentiment

Score: 8

Explanation: The announcement of Phase 3 initiation for a drug with a novel multi-MOA in a large market (DME), supported by positive preclinical and Phase 2 data, and a strong cash position, is a significant positive development for the company. The FDA alignment on the approval pathway further de-risks the program.

Positives

• Initiation of the pivotal Phase 3 program for DURAVYU in DME targets a multi-billion-dollar retinal disease market.
• New preclinical data demonstrates DURAVYU's multi-mechanism of action, inhibiting both VEGF and IL-6 mediated inflammation, addressing a critical unmet need in DME.
• Positive end of Phase 2 meeting with the FDA and alignment on an established non-inferiority approval pathway for DME.
• Phase 2 VERONA trial showed rapid and sustained improvements in vision and anatomical control with a single DURAVYU 2.7mg dose, with a continued favorable safety and tolerability profile.
• DURAVYU offers sustained drug delivery for at least six months, potentially reducing treatment burden compared to existing therapies.
• A strong cash position of over $200 million as of September 30, 2025, provides a runway into 2027, extending beyond key wet AMD data readouts.
• DURAVYU is positioned to be the first TKI to market in two significant indications: wet AMD and DME.
• A commercial manufacturing facility is underway in Northbridge, MA, built to US FDA and EU EMA standards, to support future NDA filing and commercial launch.

Risks

• Uncertainties exist regarding the timing, progress, and results of clinical development activities, including DURAVYU.
• There are uncertainties and delays relating to communications with the U.S. Food and Drug Administration (FDA) and the ability to obtain regulatory approval for the commercialization of DURAVYU.
• Unanticipated costs and expenses may arise during development and commercialization.
• The company's cash and cash equivalents may not be sufficient to support its operating plan for as long as anticipated.
• Results of clinical trials may not be predictive of future results, and interim and preliminary data are subject to further analysis and may change as more data becomes available.
• Unexpected safety or efficacy data could be observed during clinical trials.
• Uncertainties are related to the regulatory authorization or approval process and available development and regulatory pathways for approval of product candidates.
• Changes in the regulatory environment or disruptions at the FDA (e.g., workforce reduction, inadequate funding) could impact operations.
• Changes in U.S. and international trade policies or the impact of government shutdowns could affect business operations.
• Changes in expected or existing competition may impact market share and profitability.
• The success of current and future license agreements is not guaranteed.
• Dependence on contract research organizations and other outside vendors and service providers poses operational risks.
• Product liability claims could arise.
• The impact of general business and economic conditions may affect financial performance.
• Protection of intellectual property and avoiding intellectual property infringement are critical.
• Retention of key personnel is essential for continued success.
• Delays, interruptions, or failures in the manufacture and supply of product candidates could occur.
• The availability of and the need for additional financing, and the company's ability to obtain additional funding, are ongoing concerns.
• Uncertainties exist regarding the timing and results of the August 2022 subpoena from the U.S. Attorney's Office for the District of Massachusetts.
• Uncertainties exist regarding the FDA warning letter pertaining to the Watertown, MA manufacturing facility.

Future Outlook

EyePoint Pharmaceuticals anticipates first patient dosing in its pivotal Phase 3 DME trials in Q1 2026, positioning DURAVYU to be the first TKI to market in both wet AMD and DME. Topline data for the wet AMD Phase 3 LUGANO trial is expected in mid-2026, with the LUCIA trial anticipated shortly after. The company believes DURAVYU has the potential for two blockbuster indications and is positioned for clinical and commercial success through its de-risked trial designs and real-world application in multiple retinal disease indications.

Management Comments

• "Following a positive end of Phase 2 meeting with the FDA, we are pleased to announce the initiation of our Phase 3 pivotal trials for DME, following an established non-inferiority approval pathway for this important indication." Ramiro Ribeiro, M.D., Ph.D., Chief Medical Officer at EyePoint.
• "Our new preclinical data demonstrates that in addition to the known blockage of VEGF, DURAVYU also blocks IL-6 mediated inflammation via inhibition of the JAK receptors, particularly JAK-1, making DURAVYU a potential multi-MOA option for physicians and patients." Ramiro Ribeiro, M.D., Ph.D., Chief Medical Officer at EyePoint.
• "Our Phase 3 pivotal program preparations are well underway, and we anticipate dosing our first patient in the first quarter of 2026 positioning DURAVYU to be the first TKI to market in two significant indications." Ramiro Ribeiro, M.D., Ph.D., Chief Medical Officer at EyePoint.
• "The retinal community is enthusiastic to see this program move forward in DME, and for the possibility of achieving better outcomes for our patients." Roger A. Goldberg, MD, MBA, Vitreoretinal Surgeon at Bay Area Retina Associates.

Industry Context

Diabetic Macular Edema (DME) and wet Age-related Macular Degeneration (wet AMD) collectively represent over 80% of the total branded retinal disease market, with DME alone projected to reach a $3.0 billion global market by 2030. Despite the availability of current anti-VEGF therapies, a significant unmet need persists for more durable treatments and those that effectively address inflammation, as up to two-thirds of DME patients continue to experience active disease after anti-VEGF loading. DURAVYU's novel multi-mechanism of action, targeting both VEGF and IL-6, positions it to address these multifactorial aspects of DME, potentially offering a superior and less burdensome sustained-delivery treatment option compared to existing standard-of-care intravitreal injections.

Comparison to Industry Standards

• DURAVYU's Phase 3 DME trials (COMO and CAPRI) are designed as non-inferiority studies, comparing its efficacy to on-label 2mg aflibercept, a current standard of care in DME.
• The Phase 2 VERONA trial data for DURAVYU 2.7mg (single dose + aflibercept 2mg on Day 1) demonstrated comparable visual acuity improvements to the BARDENAS Phase 2 trial's anti-IL6 (vamikibart) + ranibizumab dosed monthly, but with significantly fewer injections (two vs. twelve).
• DURAVYU aims to provide sustained drug delivery for at least six months, offering a potentially superior dosing interval and reduced treatment burden compared to short-acting anti-VEGF biologics that require frequent intravitreal injections.
• The multi-MOA of vorolanib (VEGF and IL-6 inhibition) addresses the multifactorial nature of DME, which is an advantage over single-mechanism anti-VEGF therapies that may not fully control inflammation.

Legal Proceedings

• Uncertainties regarding the timing and results of the August 2022 subpoena from the U.S. Attorney's Office for the District of Massachusetts.
• Uncertainties regarding the FDA warning letter pertaining to the Watertown, MA manufacturing facility.

Stakeholder Impact

• Shareholders: Potential for increased shareholder value due to the advancement of a key pipeline asset into Phase 3 for a large market, supported by strong preclinical data and a solid cash runway.
• Patients (DME/wet AMD): Potential for a new, more effective, and less burdensome sustained-delivery treatment option that addresses both VEGF and inflammation, improving vision and quality of life.
• Physicians: A potential multi-MOA treatment option with a favorable dosing interval, addressing unmet needs in DME management and offering a differentiated therapeutic approach.
• Employees: Continued stability and growth opportunities as the company advances its clinical programs and manufacturing capabilities, potentially leading to commercialization.
• Regulatory Authorities (FDA): Continued engagement through the Phase 3 program and eventual New Drug Application (NDA) submission process.

Next Steps

• First patient dosing in pivotal Phase 3 DME trials (COMO and CAPRI) anticipated in Q1 2026.
• Topline 56-week data for the wet AMD Phase 3 LUGANO trial expected mid-2026.
• Topline data for the wet AMD Phase 3 LUCIA trial anticipated shortly after LUGANO.
• Presentation of preclinical data on JAK/IL-6 inhibition at the Eyecelerator meeting at AAO 2025.
• Completion of review by the company's independent registered public accounting firm for the quarterly report for the period ended September 30, 2025.

Key Dates

Recommendation

The initiation of a pivotal Phase 3 program for DURAVYU in DME, a multi-billion-dollar market, is a major de-risking event. The new preclinical data supporting a multi-MOA (VEGF and IL-6 inhibition) addresses a significant unmet need in DME and differentiates DURAVYU from existing therapies. Combined with positive Phase 2 data, FDA alignment on the approval pathway, and a robust cash runway extending beyond key wet AMD data, this announcement significantly enhances the company's long-term value proposition and commercial potential. The prospect of being the first TKI to market in two major retinal indications makes this a compelling investment opportunity.

Keywords

DURAVYU, vorolanib, diabetic macular edema, DME, wet AMD, age-related macular degeneration, Phase 3, clinical trial, sustained delivery, tyrosine kinase inhibitor, TKI, VEGF, IL-6, Durasert E, retinal disease, EyePoint Pharmaceuticals, EYPT, biopharmaceutical